Cancer cells often exhibit altered metabolism, such as increased glucose uptake and reliance on glycolysis, even in the presence of oxygen (known as the Warburg effect). This metabolic reprogramming creates vulnerabilities that can be targeted with drugs that disrupt these pathways, such as inhibitors of glycolysis or enzymes involved in lipid metabolism.
